Whitehawk Therapeutics
WHWK
18 hedge funds and large institutions have $4.26M invested in Whitehawk Therapeutics in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.19% less ownership
Funds ownership: 1.46% → 1.27% (-0.19%)
18% less funds holding
Funds holding: 22 → 18 (-4)
23% less capital invested
Capital invested by funds: $5.54M → $4.26M (-$1.28M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$27.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.59K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.23K |
| 5 |
BlackRock
New York
|
+$3.87K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$510K |
| 2 |
JIC
Johnson Investment Counsel
Cincinnati,
Ohio
|
-$200K |
| 3 |
Two Sigma Investments
New York
|
-$18.4K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$7K |
| 5 |
TI
Truepoint Inc
Cincinnati,
Ohio
|
-$6K |
WHWK Hedge Fund Activity: Q1 2020 in Review
18 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2020, worth a combined $4.26M — down 23% from $5.54M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of WHWK and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $27.4K. The largest seller was Goldman Sachs, exiting entirely with an estimated $510K sold.
- 18 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2020, down from 22 in Q4 2019.
- Funds reported $4.26M of Whitehawk Therapeutics stock for Q1 2020, down 23% quarter-over-quarter.
- 2 funds opened new Whitehawk Therapeutics positions in Q1 2020 and 5 closed out, a net change of -3 holders.
- The largest Whitehawk Therapeutics buyer in Q1 2020 was Renaissance Technologies, an estimated $27.4K added.
- The largest Whitehawk Therapeutics seller in Q1 2020 was Goldman Sachs, an estimated $510K sold.
Based on aggregated 13F filings for Q1 2020.